buspirone for Sleep Apnea

John D. Dingell VA Medical Center, Detroit, MI, Detroit, MI
Targeting 2 different conditionsAcetazolamide + supplemental oxygen + PAP therapy +2 morePhase 4RecruitingLed by M Safwan Badr, MDResearch Sponsored by VA Office of Research and Development

Study Summary

This trial is investigating ways to better treat central sleep apnea, a breathing disorder which is common in patients with heart failure or those using pain medications. Current treatment for central sleep apnea is positive airway pressure therapy, which is not very effective. The goal of this proposal is to find new, better ways to treat central sleep apnea by testing combination therapies including positive airway pressure and a pharmacological agent. The investigators hope that the findings of this trial will help to improve treatment and quality of life for Veterans suffering from central sleep apnea.

Eligible Conditions
  • Sleep Apnea
  • Able-bodied


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~120 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 120 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
CO2 reserve
Central apnea indices
Secondary outcome measures
% stable breathing
Carotid body function
Controller gain
+3 more

Awards & Highlights

Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.

Trial Design

3Treatment groups
Active Control
Group I: buspironeActive Control1 Intervention
To determine the effect of augmenting serotonin A1 receptor activity on breathing during sleep. The investigators hypothesize that administration of PAP and buspirone, a serotonin A1 receptor agonist; will reduce the propensity to central apnea during sleep in Veterans with CSA compared to PAP plus placebo.
Group II: acetazolamideActive Control1 Intervention
To determine the effect of dampening chemoreceptor sensitivity AND decreasing plant gain. The investigators hypothesize that combined therapy with PAP, acetazolamide and oxygen will be superior to PAP plus each intervention alone or placebo in reducing CAHI and the CO2 reserve during sleep in Veterans with CSA.
Group III: zolpidemActive Control1 Intervention
To determine the effect of decreasing respiratory-related arousals on the propensity to develop central apnea. The investigators hypothesize that administration of PAP and zolpidem, will decrease respiratory-related arousals, CAHI and the CO2 reserve during sleep in Veterans with CSA compared to PAP plus placebo.

Find a site

Who is running the clinical trial?

VA Office of Research and DevelopmentLead Sponsor
1,565 Previous Clinical Trials
2,896,234 Total Patients Enrolled
9 Trials studying Sleep Apnea
1,228 Patients Enrolled for Sleep Apnea
M Safwan Badr, MDPrincipal Investigator
John D. Dingell VA Medical Center, Detroit, MI

Media Library

buspirone Clinical Trial Eligibility Overview. Trial Name: NCT04118387 — Phase 4
Sleep Apnea Research Study Groups: buspirone, acetazolamide, zolpidem
Sleep Apnea Clinical Trial 2023: buspirone Highlights & Side Effects. Trial Name: NCT04118387 — Phase 4
buspirone 2023 Treatment Timeline for Medical Study. Trial Name: NCT04118387 — Phase 4

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What conditions or symptoms is buspirone typically employed to manage?

"Usually, salicylate poisoning is managed with the medication buspirone. Additionally, this pharmaceutical agent can be prescribed to address edema, open angle glaucoma (OAG), and other types of glaucoma."

Answered by AI

Is buspirone accepted as a safe and efficacious therapeutic for humans?

"Based on the Phase 4 status of buspirone, our team at Power has assessed its safety as a 3. This classification indicates that this pharmaceutical is sanctioned for public use."

Answered by AI

What objectives do investigators seek to accomplish with this research endeavor?

"Over the course of 4 months, researchers will be monitoring several indices to ascertain the primary outcome: carbon dioxide reserve. Secondary measurements include % stable breathing (VE/VT coefficient), carotid body function (ventilation in response to 100% oxygen), and controller gain (ventilatory response to end-tidal PCO2)."

Answered by AI

What evidence exists for the efficacy of buspirone in other medical studies?

"Currently, 29 studies are being conducted to explore the medical efficacy of buspirone. 4 trials have reached Phase 3 and 43 sites throughout the United States are researching it, particularly in Silver Spring, Maryland."

Answered by AI

Is this research endeavor currently recruiting participants?

"According to the information found on clinicaltrials.gov, this research endeavour is open for participation and has been since it was first posted in early July 2021; its latest update date being December 27th of that same year."

Answered by AI

What is the scale of participation in this clinical trial?

"Affirmative. Clinicaltrials.gov verifies that this clinical trial is actively searching for participants; the initial post was made on July 1st, 2021 and recently updated on December 27th of the same year. Two hundred patients are sought from a single site."

Answered by AI
~39 spots leftby Jun 2024